{
    "clinical_study": {
        "@rank": "52032", 
        "arm_group": [
            {
                "arm_group_label": "Desmopressin", 
                "arm_group_type": "Experimental", 
                "description": "0,3 mcg per kilogram of desmopressin in 100 ml of saline, labeled as \"study drug\" and administered  in 30 minutes a half hour before surgical incision"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "100 of saline labeled as \"study drug\" administered in 30 minutes a half hour before surgical incision"
            }
        ], 
        "brief_summary": {
            "textblock": "Acquired Von Willebrand disease (type 2A) has been described in patients with severe aortic\n      stenosis, the association of aortic stenosis and Digestive bleeding due to this phenomena\n      has received the name of Heye\u00b4s syndrome.\n\n      We propose that administering Desmopressin (DDAVP) in patients scheduled to aortic valve\n      replacement surgery will reduce blood loss and transfusion rate.\n\n      this was a pilot study"
        }, 
        "brief_title": "Severe Aortic Stenosis and Acquired Von Willebrand\u00b4s Disease: The Impact of Desmopressin in Valve-Replacement Surgery", 
        "completion_date": {
            "#text": "February 2010", 
            "@type": "Actual"
        }, 
        "condition": [
            "Acquired Von Willebrand Disease Secondary to Severe Aortic Stenosis", 
            "Heye\u00b4s Syndrome", 
            "Severe Aortic Stenosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Aortic Valve Stenosis", 
                "Constriction, Pathologic", 
                "Von Willebrand Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "Randomized Controlled trial compared with placebo in a double blind fashion. Subjects with\n      severe aortic stenosis (transvalvular gradient >50 mmHg or valvular area of lass than 1 cm2)\n      scheduled for aortic valve replacement were enrolled.\n\n      the day of surgery blood samples were taken in order to confirm diagnosis (factor VIII\n      activity and Protein electrophoresis for Von Willebrand\u00b4s multimers) and then 0,3 mcg/k of\n      DDAVP or saline equally labeled as \"study drug\" were administered en 30 minutes a half hour\n      before incision.\n\n      Blood loss, postoperative hematocrit and transfusion requirement were measured, plasma\n      sodium was measured as a safety issue."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  severe aortic stenosis defined as mean transvalvular gradient greater or equal to 40\n             mmHg ot transvalvular area less than 1 cm2\n\n          -  scheduled for aortic valve replacement surgery\n\n        Exclusion Criteria:\n\n          -  combined surgery (plus coronary artery bypass graft or other valve\n             replacement/plasty)\n\n          -  Infective Endocarditis\n\n          -  previously known haemostatic disorder\n\n          -  previous treatment with oral anticoagulants or IIb-IIIa inhibitors (we did not\n             exclude those on acetyl-salicylic acid)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "13", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01994330", 
            "org_study_id": "RVA"
        }, 
        "intervention": {
            "arm_group_label": "Desmopressin", 
            "description": "0.3 mcg per kilogram administered in 30 minutes a half hour previous to surgical incision", 
            "intervention_name": "desmopressin", 
            "intervention_type": "Drug", 
            "other_name": "DDAVP"
        }, 
        "intervention_browse": {
            "mesh_term": "Deamino Arginine Vasopressin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "acquired von Willebrand disease", 
            "severe aortic stenosis", 
            "Heye\u00b4s syndrome", 
            "desmopressin", 
            "von Willebrand multimers"
        ], 
        "lastchanged_date": "November 19, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Santiago", 
                    "country": "Chile", 
                    "state": "Region Metropolitana"
                }, 
                "name": "Hospital Cl\u00ednico Universidad Cat\u00f3lica de Chile"
            }
        }, 
        "location_countries": {
            "country": "Chile"
        }, 
        "number_of_arms": "2", 
        "official_title": "Severe Aortic Stenosis and Acquired Von Willebrand\u00b4s Disease: The Impact of Desmopressin in Valve-Replacement Surgery", 
        "other_outcome": [
            {
                "description": "blood sampling for plasma sodium in specified time frame", 
                "measure": "incidence of hyponatremia", 
                "safety_issue": "Yes", 
                "time_frame": "18-24 hours post administration of study drug"
            }, 
            {
                "description": "blood sampling for von Willebrand study:\ncollagen binding activity\nristocetin factor test\ncoagulation factor VIII activity\nvon Willebrand factor antigen\nRistocetin cofactor test/von Willebrand factor antigen ratio and protein electrophoresis of von Willebrand multimers", 
                "measure": "von Willebrand study and protein electrophoresis", 
                "safety_issue": "No", 
                "time_frame": "the day of surgery, half hour previos to administration of study drug"
            }
        ], 
        "overall_official": [
            {
                "affiliation": "Pontificia Universidad Catolica de Chile", 
                "last_name": "esperanza carrasco, anesthesiologist", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Pontificia Universidad Catolica de Chile", 
                "last_name": "rodrigo lopez, anesthesiologist", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Pontificia Universidad Catolica de Chile", 
                "last_name": "guillermo lema, profesor titular", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Chile: Comit\u00e9 de \u00c9tica Cient\u00edfico", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Blood loss obtained from fluid balance of surgery plus drain output", 
            "measure": "blood loss", 
            "safety_issue": "No", 
            "time_frame": "once patient arrives to post anesthesia care unit (approximately 6 hours after drug administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01994330"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Pontificia Universidad Catolica de Chile", 
            "investigator_full_name": "MPoblete", 
            "investigator_title": "Anesthesiologist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "hematocrit and hemoglobin in time frame mentioned", 
                "measure": "postoperative hematocrit", 
                "safety_issue": "No", 
                "time_frame": "the morning after surgery (18-24 hours after drug administration)"
            }, 
            {
                "description": "transfusion of packaged red cells units until 48 hours after administration of study drug", 
                "measure": "need of transfusion", 
                "safety_issue": "No", 
                "time_frame": "48 hours post administration"
            }
        ], 
        "source": "Pontificia Universidad Catolica de Chile", 
        "sponsors": {
            "collaborator": {
                "agency": "Ferring Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Pontificia Universidad Catolica de Chile", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}